Log In Sign up
The largest database of trusted experimental protocols
> Chemicals & Drugs > Organic Chemical > Epirubicin

Epirubicin

Epirubicin is a semisynthetic analog of the antineoplastic antibiotic doxorubicin.
It is used in the treamtent of a variety of cancers, including breast, ovarian, and bladder cancer.
Epirubicin intercalates into DNA and disrupts topoisomerase II activity, leading to cell death.
Compared to doxorubicin, epirubicin has a more favorable toxicity profile with reduced cardiotoxicity.
Researchers can optimize epirubicin studies using PubCompare.ai, an AI-driven protocol comparison tool that helps identify the most reproducible and accurate findings from literature, preprints, and patents.
This intuitive platform unlocks the best protocols and products for epirubicin research.

Most cited protocols related to «Epirubicin»

1
Tracking TNBC Response to Neoadjuvant Chemo
Cited 16 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2018
Bevacizumab Core Needle Biopsy Docetaxel Epirubicin Fishes Freezing Immunohistochemistry Inflammatory Breast Carcinoma Lymph Node Metastasis Malignant Neoplasm of Breast Malignant Neoplasms Neoplasms Operative Surgical Procedures Patients Tissues Triple Negative Breast Neoplasms
2
Harmonized Cardiomyopathy Surveillance Recommendations
Cited 13 times

Protocol full text hidden due to copyright restrictions

Open the protocol to access the free full text link

Publication 2015
Abdomen Adult Anthracyclines Anthraquinones Cardiologists Cardiomyopathies Cardiotoxicity Cardiovascular System Carotid Artery Diseases Chest Child Clinical Reasoning Congenital Abnormality Coronary Artery Disease Daunorubicin Diastole Doxorubicin Electric Conductivity Epidemiologists Epirubicin Fibrosis Genetic Heterogeneity Heart Heart Failure Idarubicin Leukemia Malignant Neoplasms Mediastinum Mitoxantrone Neoplasms North American People Nurses Oncologists Pericardium Pharmacotherapy Population Group Radiation Oncologists Radiotherapy Stenosis Survivors of Childhood Cancer Systole Therapeutics Whole-Body Irradiation
3
Retrospective TNBC Cohort Analysis
Cited 8 times
In Sweden, the definition of TNBC is a tumor with ≤10% of cells with IHC-staining for ER and PR (thus including tumors with 1-10% stained cells) and an IHC HER2-staining score < 2, or for patients with IHC 2+ a non-amplified ISH-status. During September 1 2010 to March 31 2015, 408 patients were diagnosed with TNBC (localized or advanced disease with specified treatment status) in the Skåne healthcare region in southern Sweden, Scandinavia, based on data from the Swedish national breast cancer quality registry (NKBC) (Figure 1). 340 of these patients were enrolled in the SCAN-B study5 (link),33 (link),34 (link) (ClinicalTrials.gov ID NCT02306096), which is a prospective, observational, population-based cohort study, from which 254 with concurrent RNAseq were selected for extensive clinical review and WGS. Of reviewed cases, 153 (60%) patients were eligible for OS/IDFS survival analysis after standard of care adjuvant chemotherapy (FEC-based [combination of 5 fluorouracil, epirubicin, and cyclophosphamide] ± a taxane in 96% of cases) according to national guidelines. Of these (irrespective of clinical endpoint status), 41% had ≥5 years of follow-up, 25% 4-5 years, 31% 2-4 years, and 4% <2 years of follow-up. 148 of 153 patients (97%) were eligible for relapse analysis, of which 20% developed a relapse of some type (loco-regional or distant). Remaining cases received either neoadjuvant treatment, no adjuvant treatment (n=58), or were not treated in an adjuvant context (e.g. metastatic disease at diagnosis). As part of routine oncogenetic clinical screening, 49 of 254 recruited patients were previously screened for pathogenic germline variants in BRCA1 and BRCA2, with 12 positive findings (nine BRCA1- and three BRCA2-carriers). Patient cohort characteristics, enrolled SCAN-B patients, WGS analysed SCAN-B patients, and WGS analysed SCAN-B treatment subsets are described in Supplementary Table S2. Individual patient characteristics are provided in the Supplementary Data Table.
Staaf J., Glodzik D., Bosch A., Vallon-Christersson J., Reuterswärd C., Häkkinen J., Degasperi A., Amarante T.D., Saal L.H., Hegardt C., Stobart H., Ehinger A., Larsson C., Rydén L., Loman N., Malmberg M., Kvist A., Ehrencrona H., Davies H.R., Borg Å, & Nik-Zainal S. (2019). Whole-genome-sequencing of triple negative breast cancers in a population-based clinical study. Nature medicine, 25(10), 1526-1533.
Publication 2019
BRCA1 protein, human Cells Chemotherapy, Adjuvant Cyclophosphamide Diagnosis Epirubicin ERBB2 protein, human Fluorouracil Gene, BRCA2 Germ-Line Mutation Malignant Neoplasm of Breast Neoadjuvant Therapy Neoplasm Metastasis Neoplasms Neoplastic Cell Transformation pathogenesis Patients Pharmaceutical Adjuvants Radionuclide Imaging Relapse taxane
4
Drug Testing on Gastric Organoids
Cited 8 times
Human gastric cancer and normal gastric organoids were cultured as described earlier and were passaged twice a week with a split ratio of 1:2/1:3.20 (link) Treatment with chemotherapeutics was performed 24 hours after seeding using 5-FU, oxaliplatin, irinotecan, epirubicin and docetaxel. Selected organoids were treated with trastuzumab (Herceptin, Roche), palbociclib (No S1116, Selleckchem) and imatinib (No ST1571, Selleckchem). Further information is given in the online supplementary methods.
Seidlitz T., Merker S.R., Rothe A., Zakrzewski F., von Neubeck C., Grützmann K., Sommer U., Schweitzer C., Schölch S., Uhlemann H., Gaebler A.M., Werner K., Krause M., Baretton G.B., Welsch T., Koo B.K., Aust D.E., Klink B., Weitz J, & Stange D.E. (2018). Human gastric cancer modelling using organoids. Gut, 68(2), 207-217.
Publication 2018
A-A-1 antibiotic Docetaxel Epirubicin Gastric Cancer Herceptin Homo sapiens Imatinib Irinotecan Organoids Oxaliplatin palbociclib Pharmacotherapy ST 1571 Stomach Trastuzumab
5
Breast Cancer Molecular Profiling Protocol
Cited 8 times
There was ethical review and approval for all protocols used in this study from the respective centers involved and all subjects gave written informed consent to participate. A training set was developed using 171 breast samples, comprised of 16 “normal” breast tissue samples from reduction mammoplasties or grossly uninvolved breast tissue and 155 primary invasive breast cancers. These samples were collected from 2005–2009 under IRB approved protocols at the University of Utah and the University of North Carolina at Chapel Hill. Clinical-pathological information associated with the samples is based on the College of American Pathology (CAP) and American Joint Committee on Cancer (AJCC) standards at the time of collection (Additional file 1). Subtype classification and single and meta-gene (proliferation) scores were predicted on an independent test set of 814 samples from the GEICAM/9906 clinical trial, a randomized Phase 3 trial of fluorouracil, epirubicin, and cyclophosphamide alone or followed by paclitaxel [22 (link)]. Patients that were hormone receptor positive (ER and/or PR positive by IHC) were given adjuvant tamoxifen. The hormone receptor status for these samples was evaluated at a single site (Department of Pathology, Hospital General Universitario de Alicante) using immunohistochemistry (IHC) for progesterone receptor (PR) (clone PgR636, DAKO, Glostrup, Denmark) and estrogen receptor (ER) (clone 1D5, DAKO, Glostrup, Denmark) (Additional file 2). The scores for the proportion of dyed cells and intensity were summed to obtain a total Allred Score [23 ]. Measurement of HER2 expression was performed by Herceptest™ (DAKO, Glostrup, Denmark) and samples with scores of 2+ by IHC were confirmed by CISH, following the ASCO/CAP guidelines [24 (link)]. The clinical data for the training set and GEICAM/9906 test set are summarized in Table 1.
Bastien R.R., Rodríguez-Lescure Á., Ebbert M.T., Prat A., Munárriz B., Rowe L., Miller P., Ruiz-Borrego M., Anderson D., Lyons B., Álvarez I., Dowell T., Wall D., Seguí M.Á., Barley L., Boucher K.M., Alba E., Pappas L., Davis C.A., Aranda I., Fauron C., Stijleman I.J., Palacios J., Antón A., Carrasco E., Caballero R., Ellis M.J., Nielsen T.O., Perou C.M., Astill M., Bernard P.S, & Martín M. (2012). PAM50 Breast Cancer Subtyping by RT-qPCR and Concordance with Standard Clinical Molecular Markers. BMC Medical Genomics, 5, 44.
Full text: Click here
Publication 2012
Breast CISH protein, human Clone Cells Cyclophosphamide Epirubicin ERBB2 protein, human Estrogen Receptors Ethical Review Fluorouracil Genes Hormones Immunohistochemistry Joints Malignant Neoplasm of Breast Malignant Neoplasms Mammaplasty Paclitaxel Patients Pharmaceutical Adjuvants Receptors, Progesterone Tamoxifen Tissues

Most recents protocols related to «Epirubicin»

1
Phase II Trial of EGFR-Targeted Therapy in Metastatic TNBC
This prospective, proof-of concept, open-label multicenter phase II trial (SAKK 24/14; NCT02833766) was designed with a single-stage single-arm layout. We accrued patients at 12 participating sites across Switzerland.
Patients met inclusion criteria if they presented with metastatic or locally advanced, inoperable TNBC with an EGFR expression of at least (1 +) on immunohistochemistry according to the EGFR pharmDx™ Interpretation Guidelines17 . Staining was conducted with the ready-to-use K1492 EGFR pharmDx™ kit for manual use after antigen retrieval for 24 min with the CC1 buffer of Ventana/Roche and incubation for 32 min in the automated immunostainer Benchmark Ultra of Ventana/Roche. Only patients with measurable or evaluable disease, ≥ 18 years, with a WHO performance status of 0–2, and no prior systemic treatment for metastatic or inoperable disease, were considered eligible. Patients with evidence of CNS or leptomeningeal metastases (even if previously treated) or with a history of hematologic or primary solid malignancy (other than TNBC) were excluded (unless in remission for at least 5 years). Inclusion of adequately treated cervical carcinoma in situ or localized non-melanoma skin cancer was permitted. Adjuvant treatment must have been stopped at least 6 months before registration and previous treatment with anthracyclins must not have exceeded 240 mg/m2 of doxorubicin or 450 mg/m2 of epirubicin.
Mamot C., Wicki A., Hasler-Strub U., Riniker S., Li Q., Holer L., Bärtschi D., Zaman K., von Moos R., Dedes K.J., Boos L.A., Novak U., Bodmer A., Ritschard R., Obermann E.C., Tzankov A., Ackermann C., Membrez-Antonioli V., Zürrer-Härdi U., Caspar C.B., Deuster S., Senn M., Winterhalder R, & Rochlitz C. (2023). A multicenter phase II trial of anti-EGFR-immunoliposomes loaded with doxorubicin in patients with advanced triple negative breast cancer. Scientific Reports, 13, 3705.
Full text: Click here
Publication 2023
Antigens Buffers Cervical Cancer Doxorubicin EGFR protein, human Epirubicin Familial Atypical Mole-Malignant Melanoma Syndrome Immunohistochemistry Malignant Neoplasms Neoplasm Metastasis Patients Pharmaceutical Adjuvants
2
Neoadjuvant and Adjuvant Pembrolizumab for eTNBC
The target population was patients with high-risk eTNBC, based on the population of KEYNOTE-522. Patients in KEYNOTE-522 were randomized to pembrolizumab + chemotherapy/pembrolizumab or placebo + chemotherapy/placebo arms. In the neoadjuvant phase, pembrolizumab (at a dose of 200 mg) or placebo was administered once every 3 weeks (q3w) up to eight cycles, and the chemotherapy consisted of four cycles of paclitaxel (80 mg/m2 once weekly [qw]) and carboplatin (area under the curve [AUC5]) q3w or AUC 1.5 qw in the first 12 weeks), followed by four cycles of doxorubicin (60 mg/m2) or epirubicin (90 mg/m2) plus cyclophosphamide (600 mg/m2 q3w in the subsequent 12 weeks). Each subject underwent definitive surgery 3–6 weeks after conclusion of the neoadjuvant treatment. In the adjuvant phase, pembrolizumab 200 mg or placebo was administered q3w for up to nine cycles. Postoperative radiation therapy was acceptable in accordance with the standard of care as applicable.
Huang M., A. Fasching P., Haiderali A., Xue W., Yang C., Pan W., Zhou Z.Y., Hu P., Chaudhuri M., Le Bailly De Tilleghem C., Cappoen N, & O’Shaughnessy J. (2023). Cost-Effectiveness of Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant Single-Agent Pembrolizumab for High-Risk Early-Stage Triple-Negative Breast Cancer in the United States. Advances in Therapy, 40(3), 1153-1170.
Publication 2023
Arm, Upper Carboplatin Cyclophosphamide Doxorubicin Epirubicin Neoadjuvant Therapy Operative Surgical Procedures Paclitaxel Patients pembrolizumab Pharmaceutical Adjuvants Pharmacotherapy Placebos Radiotherapy Target Population
3
Neoadjuvant Chemotherapy Regimens for Breast Cancer
The neoadjuvant chemotherapy regimens in this study were conducted as follows:

TEC (docetaxel 75 mg/m2, epirubicin 75 mg/m2, and cyclophosphamide 500 mg/m2,, every 3 weeks for 6 cycles).

EC-T/EC-TH (epirubicin 90 mg/m2 and cyclophosphamide 600 mg/m2 every 3 weeks for 4 cycles, followed by docetaxel 100 mg/m2 and/or trastuzumab 8 mg/kg loading dose, 6 mg/kg maintenance dose, every 3 weeks for 4 cycles).

TCH (docetaxel 75 mg/m2, carboplatin AUC 6, and trastuzumab 8 mg/kg loading dose, 6 mg/kg maintenance dose, every 3 weeks for 6 cycles).

TC (docetaxel 75 mg/m2 and cyclophosphamide 600 mg/m2, every 3 weeks for 4 cycles).

TEC, EC-T, and EC-TH are taxane-plus-anthracyclines-based regimens; TC and TCH are taxane-based regimens.
Ma Y., Lv M., Yuan P., Chen X, & Liu Z. (2023). Dyslipidemia is associated with a poor prognosis of breast cancer in patients receiving neoadjuvant chemotherapy. BMC Cancer, 23, 208.
Full text: Click here
Publication 2023
Anthracyclines Carboplatin Cyclophosphamide Docetaxel Epirubicin Neoadjuvant Chemotherapy taxane Trastuzumab Treatment Protocols
4
Transarterial Chemoembolization Techniques
Hepatic arteriography and superior mesenteric arteriography were performed to assess the feeding arteries of the tumor. Subsequently, a microcatheter was inserted into the tumor-feeding arteries.
Conventional TACE (cTACE) was an intra-arterial injection of 40–60 mg of epirubicin (Pharmorubicin; Pfizer, Wuxi, China) mixed with 5–20 mL of lipiodol (Jiangsu Hengrui Medicine Co., Ltd., Jiangsu, China). When needed, embosphere (100–300 μm) was used for further embolization to achieve stasis.
Drug-eluting bead TACE (DEB-TACE) was performed by CallSpheres® (Jiangsu Hengrui Medicine Co., Ltd., Jiangsu, China) beads (100–300 μm) loaded with doxorubicin (40–60 mg). CalliSpheres® beads and non-ionic contrast agent were mixed by 1:1 and injected at a speed of 1 mL/min. The injection was completed during the stasis flow of contrast agent.
TACE was repeated “on demand” after our multidisciplinary team (MDT) discussion depending on the results of examinations, including MRI/CT, AFP level, hematological and biochemical indices.
Yang X., Deng H., Sun Y., Zhang Y., Lu Y., Xu G, & Huang X. (2023). Efficacy and Safety of Regorafenib Plus Immune Checkpoint Inhibitors with or Without TACE as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: A Propensity Score Matching Analysis. Journal of Hepatocellular Carcinoma, 10, 303-313.
Publication 2023
ADAM17 protein, human Arteries Arteriography Contrast Media Doxorubicin Embolization, Therapeutic Epirubicin Farmorubicin Lipiodol Mesentery Neoplasms Pharmaceutical Preparations Physical Examination
5
Chemotherapy and Immunotherapy in TNBC
The chemotherapy trial was from the southwest hospital containing 15 TNBC patients with TE regimen (paclitaxel/docetaxel, epirubicin) or TEC regimen (docetaxel, epirubicin and cyclophosphamide) for neoadjuvant chemotherapy. The biopsies were taken at their first to doctor as pre-chemotherapy samples and the intraoperative specimens were taken after the neoadjuvant treatment as post-chemotherapy samples. The immunotherapy cohort was from the FUTURE trial C arm (NCT03805399). These patients were with locally advanced or metastatic TNBC progressed after standard chemotherapy including taxol. Intraoperative specimens were taken in the radical mastectomy or modified mastectomy as pre-chemotherapy samples. With standard chemotherapy failure, the progressive and unresectable tumor biopsies were taken as post-chemotherapy samples before being treated with nab-paclitaxel plus anti-PD-1 antibodies, which were regarded as the baseline of chemoimmunotherapy. For the survival analysis, we collected 399 breast cancer patients for the multicentric clinical cohort from Chongqing (147 cases), Guangzhou (89 cases) and Beijing (163 cases) trials. Most patients have undergone radical mastectomy or modified mastectomy and have received the standard chemotherapy. All procedures were approved by the Ethics Committee of the First Affiliated Hospital of Army Medical University (KY20200305). Informed consent was obtained from all patients.
Xie X.Q., Yang Y., Wang Q., Liu H.F., Fang X.Y., Li C.L., Jiang Y.Z., Wang S., Zhao H.Y., Miao J.Y., Ding S.S., Liu X.D., Yao X.H., Yang W.T., Jiang J., Shao Z.M., Jin G, & Bian X.W. (2023). Targeting ATAD3A-PINK1-mitophagy axis overcomes chemoimmunotherapy resistance by redirecting PD-L1 to mitochondria. Cell Research, 33(3), 215-228.
Full text: Click here
Publication 2023
130-nm albumin-bound paclitaxel Anti-Antibodies Biopsy Cyclophosphamide Docetaxel Epirubicin Ethics Committees, Clinical Immunotherapy Malignant Neoplasm of Breast Mastectomy, Radical Modified Radical Mastectomy Neoadjuvant Chemotherapy Neoadjuvant Therapy Neoplasms Paclitaxel Patients Pharmacotherapy Physicians Taxol TEC regimen Treatment Protocols

Top products related to «Epirubicin»

1
Epirubicin by Merck Group
Sourced in United States, United Kingdom, Germany
Epirubicin is a cancer treatment drug manufactured by Merck Group. It is an anthracycline antibiotic used in the treatment of various types of cancer. Epirubicin works by interfering with the growth and division of cancer cells.
2
Epirubicin by Pfizer
Sourced in China, United States, Japan
Epirubicin is a type of laboratory equipment used in scientific research and pharmaceutical development. It is a chemical compound that belongs to the anthracycline class of medications. Epirubicin is commonly used as a reference standard or analytical tool in various laboratory applications, such as drug testing, drug discovery, and biomedical research.
3
Pharmorubicin by Pfizer
Sourced in China, United States, France
Pharmorubicin is a laboratory equipment product manufactured by Pfizer. It is used for research and development purposes in the pharmaceutical industry.
4
Lipiodol by Guerbet
Sourced in France, United States, Germany, Italy, Japan, China
Lipiodol is a radiopaque contrast agent used in diagnostic medical imaging procedures. It is a sterile, iodinated, ethyl ester of fatty acids derived from poppy seed oil. Lipiodol is used to improve the visibility of certain structures or organs during radiographic examinations.
5
Fetal bovine serum (fbs) by Thermo Fisher Scientific
Sourced in United States, China, United Kingdom, Germany, Australia, Japan, Canada, Italy, France, Switzerland, New Zealand, Brazil, Belgium, India, Spain, Israel, Austria, Poland, Ireland, Sweden, Macao, Netherlands, Denmark, Cameroon, Singapore, Portugal, Argentina, Holy See (Vatican City State), Morocco, Uruguay, Mexico, Thailand, Sao Tome and Principe, Hungary, Panama, Hong Kong, Norway, United Arab Emirates, Czechia, Russian Federation, Chile, Moldova, Republic of, Gabon, Palestine, State of, Saudi Arabia, Senegal
Fetal Bovine Serum (FBS) is a cell culture supplement derived from the blood of bovine fetuses. FBS provides a source of proteins, growth factors, and other components that support the growth and maintenance of various cell types in in vitro cell culture applications.
6
Progreat by Terumo
Sourced in Japan, Belgium, United States
Progreat is a laboratory equipment product designed for general laboratory use. It serves as a versatile tool for various applications within the research and scientific community.
7
Cisplatin by Merck Group
Sourced in United States, Germany, United Kingdom, China, Sao Tome and Principe, Macao, Italy, France, Canada, Japan, Spain, Czechia, Poland, Australia, India, Switzerland, Sweden, Belgium, Portugal
Cisplatin is a platinum-based medication used as a chemotherapeutic agent. It is a crystalline solid that can be dissolved in water or saline solution for administration. Cisplatin functions by interfering with DNA replication, leading to cell death in rapidly dividing cells.
8
Paclitaxel by Merck Group
Sourced in United States, Germany, United Kingdom, France, China, Macao, Japan, Sao Tome and Principe, Canada, Poland, Spain, Israel, Australia, Switzerland, Italy
Paclitaxel is a pharmaceutical compound used in the production of various cancer treatment medications. It functions as a microtubule-stabilizing agent, which plays a crucial role in the development and regulation of cells. Paclitaxel is a key ingredient in the manufacture of certain anti-cancer drugs.
9
Mcf 7 by American Type Culture Collection
Sourced in United States, United Kingdom, China, Germany, France, Japan, Italy, Switzerland, Sweden, India, Canada, Egypt, Australia, Holy See (Vatican City State), Brazil
MCF-7 is a cell line derived from human breast adenocarcinoma. It is an adherent epithelial cell line that can be used for in vitro studies.
10
Lipiodol ultra fluide by Guerbet
Sourced in France, China
Lipiodol Ultra-Fluide is a radiopaque contrast agent manufactured by Guerbet. It is a water-insoluble, iodinated, ethyl ester of fatty acids derived from poppy seed oil. Lipiodol Ultra-Fluide is used for various radiological procedures to enhance visualization of anatomical structures during imaging.

More about "Epirubicin"

Epirubicin, a semisynthetic analog of the antineoplastic antibiotic doxorubicin (also known as Adriamycin), is a widely used chemotherapeutic agent in the treatment of various cancers, including breast, ovarian, and bladder cancer.
This antineoplastic compound intercalates into DNA and disrupts the activity of topoisomerase II, leading to cell death.
Compared to doxorubicin, epirubicin (also referred to as Pharmorubicin) has a more favorable toxicity profile, with reduced cardiotoxicity, making it a preferable choice in many clinical settings.
Researchers can optimize their epirubicin studies using PubCompare.ai, an AI-driven protocol comparison tool that helps identify the most reproducible and accurate findings from the scientific literature, preprints, and patents.
This intuitive platform unlocks the best protocols and products for epirubicin research, including the use of Lipiodol (a contrast agent) and FBS (fetal bovine serum) in cell culture experiments.
Researchers can also explore the combined effects of epirubicin with other chemotherapeutic agents, such as Progreat, Cisplatin, and Paclitaxel, on cancer cell lines like MCF-7 (a breast cancer cell line).
By leveraging the power of PubCompare.ai, scientists can ensure their epirubicin studies are as reproducible and accurate as possible, ultimately advancing the understanding and treatment of the targeted cancers.